What is Halozyme Therapeutics's revenue?

Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.

Is Halozyme Therapeutics profitable?

Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.

What are Halozyme Therapeutics's profit margins?

Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.

What is Halozyme Therapeutics's earnings per share?

Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.

Where does Halozyme Therapeutics's income statement data come from?

Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Halozyme Therapeutics HALO Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$1.51B+39.1%	$1.4B+37.6%	$1.24B+31.2%	$1.18B+35.0%	$1.08B+25.6%
Total cost of revenue	$259.61M+44.6%	$228.77M+43.5%	$192.06M+13.2%	$186.24M+6.4%	$179.49M-3.2%
Gross profit	$1.25B+38.0%	$1.17B+36.4%	$1.05B+35.1%	$992.43M+42.1%	$904.82M+33.6%
Gross margin	82.8%-0.7pp	83.6%-0.7pp	84.5%+2.5pp	84.2%+4.2pp	83.4%+4.9pp
Research and development	$92.25M+23.4%	$81.49M+3.1%	$70.03M-12.4%	$71.24M-9.6%	$74.74M-3.6%
Selling, general and administrative	$222.61M+37.8%	$207.09M+34.2%	$172.31M+15.1%	$167.47M+16.5%	$161.56M+9.9%
Compensation and benefits	——	——	——	——	——
Occupancy and equipment	——	——	——	——	——
Depreciation and amortization	$78.2M+9.6%	$76.66M+7.9%	$71.53M-2.4%	$71.43M-2.6%	$71.33M-3.0%
Impairment charges	——	$48.7M—	$36.53M—	$24.35M—	$12.18M—
Total costs & expenses	$996.47M+105%	$927.61M+100.0%	$505.45M+7.5%	$496M+5.3%	$486.84M+0.7%
Operating income	——	——	$737.4M+54.6%	$682.67M+69.8%	$597.47M+57.5%
Interest expense	$19.11M+5.5%	$18.13M+0.2%	$17.76M-5.4%	$17.98M-4.1%	$18.11M-3.3%
Other income (expense), net	$15.97M-37.6%	$21.47M-9.6%	$26.3M+20.3%	$27.44M+36.0%	$25.58M+39.5%
Income before income taxes	——	——	$745.94M+55.4%	$692.13M+66.1%	$604.93M+54.3%
Income tax expense	$154.53M+29.2%	$149.99M+32.7%	$150.45M+71.7%	$134.85M+69.8%	$119.57M+63.1%
Net income	——	——	$595.49M+51.7%	$557.28M+65.2%	$485.36M+52.2%
Diluted earnings per share	——	——	$4.75+57.3%	$4.37+69.4%	$3.76+55.4%
Basic earnings per share	——	——	$4.89+59.3%	$4.48+71.6%	$3.85+57.1%
Weighted-average shares, diluted	493.3M-4.3%	497M-4.0%	502.6M-3.8%	510.4M-3.0%	515.4M-2.9%
Weighted-average shares, basic	476.5M-5.4%	481.6M-5.1%	488.6M-4.7%	498.2M-3.8%	504M-3.6%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Share-based compensation expense related to employee stock plans	——	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——	——
Amortization Of Debt Discount Premium	——	——	——	——	——
Amortization of capitalized software and acquired intangible assets	$88.41M+24.4%	$76.66M+7.9%	$71.05M0.0%	$71.05M-3.5%	$71.05M-3.6%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Capital investments accrued but not yet paid	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——	——
Deferred Rent Payments	——	——	——	——	——
Effective tax rates	——	——	——	——	——
Purchase Price Adjustments	——	——	——	——	——
Accounts payable and other current liabilities	-$27.93M-174%	$6.21M-86.8%	$22.55M+278%	$6.53M-23.7%	$37.53M—
Increase (Decrease) in Accounts Receivable	$151.44M+39.3%	$128.06M+72.5%	$60.29M-11.9%	$101.82M+422%	$108.72M+8,811%
Increase (Decrease) in Deferred Income Taxes	——	——	——	——	——
Increase (Decrease) in Inventories	-$30.52M-203%	-$2.55M-104%	$23.95M—	$22.85M—	$29.71M—
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$55.76M—	-$3.04M—	$4.43M—
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——	——	-$571.1M-157%	-$530.14M—	-$221.69M—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	——	——	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$677.42M+34.4%	$651.56M+36.0%	$611M+51.6%	$547.78M+30.4%	$503.86M+16.9%
Number of operating segments	——	——	——	——	——
Expense associated with accretion of lease liabilities	——	——	——	——	——
Operating Lease Payments	——	——	——	——	——
Operating lease right-of-use assets amortization expense	——	——	——	——	——
Other Comprehensive Income Loss Before Tax	——	——	——	——	——
Net gains (losses) deferred	——	——	——	——	——
Unrealized gain (loss) on derivative instruments, net	——	——	——	——	——
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net Of Tax	——	——	——	——	——
Net unrealized gains (losses) on securities still held	——	——	——	——	——
Other income, net (Note 6)	$15.97M-37.6%	$21.47M-9.6%	$26.3M+20.3%	$27.44M+36.0%	$25.58M+39.5%
Payment for capped calls	——	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	——	——	——	——	——
Payments to Acquire Debt Securities, Available-for-Sale	$116.56M-80.2%	$247.36M-61.8%	$298.8M-51.6%	$597.82M+25.8%	$588.48M+54.2%
Payments to Acquire Property, Plant, and Equipment	$9.76M+20.5%	$6.97M-34.8%	$8.6M-16.1%	$7.08M-39.3%	$8.1M—
Proceeds From Previous Acquisition	——	——	——	——	——
Sale of investments	——	——	——	——	——
Acquired in-process research and development expenses	——	$284.89M—	$213.67M—	$142.44M—	$71.22M—
Research and development expense	——	$81.49M+3.1%	$80.88M+3.2%	$80.27M+3.3%	$79.66M+3.4%
Revenue From Contract With Customer Excluding Assessed Tax	$1.51B+39.1%	$1.4B+37.6%	$1.24B+31.2%	$1.18B+35.0%	$1.08B+25.6%
Royalties received, number of products sold	——	——	——	——	——
Stock-based compensation	$57.53M+30.2%	$51.57M+18.9%	$46.46M+11.7%	$46.87M+22.1%	$44.18M+14.7%
Granted (in shares)	——	——	——	——	——
Risk-free interest rates, high end of range (as a percent)	——	——	——	——	——
Risk-free interest rates, low end of range (as a percent)	——	——	——	——	——
Weighted-average dividend yield	——	——	——	——	——
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	——	——	——	——	——
Value of shares repurchased	——	——	——	——	——
EBIT	——	——	$737.4M+54.6%	$682.67M+69.8%	$597.47M+57.5%
EBITDA	——	——	$748.14M+53.4%	$693.31M+68.0%	$608.01M+55.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Halozyme Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's revenue?: Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
Is Halozyme Therapeutics profitable?: Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
What are Halozyme Therapeutics's profit margins?: Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
What is Halozyme Therapeutics's earnings per share?: Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
Where does Halozyme Therapeutics's income statement data come from?: Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.